Omalizumab Mechanism and Clinical Use

Primary Mechanism of Action

• Omalizumab binds to free circulating IgE at the Cε3 domain, which is the specific site where IgE normally attaches to its high-affinity receptor (FcεRI) on effector cells, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2

Clinical Context and Indications

• The National Asthma Education and Prevention Program recommends omalizumab as adjunctive therapy for patients aged 12 years and older with severe persistent allergic asthma inadequately controlled with high-dose inhaled corticosteroids plus long-acting beta-agonists, with a strength of evidence rated as high 1
• Omalizumab is specifically indicated for patients with documented atopy and proven sensitivity to perennial aeroallergens, not for non-allergic asthma, according to the American College of Allergy, Asthma, and Immunology 1